Life Sciences

Diurnal Group Plc

Founded in 2004, Diurnal is a UK-based, globally-focused specialty pharma company developing high quality products for the life-long treatment of chronic endocrine conditions. Diurnal are committed to addressing major unmet clinical and patient needs in hormone replacement, initially by developing and marketing products for the rare orphan diseases Congenital Adrenal Hyperplasia (CAH) and Adrenal Insufficiency (AI).

Through their extensive knowledge, experience and persistence Diurnal have created a specialized, valuable pipeline of product opportunities for the improved treatment of hypogonadism, hypothyroidism and other endocrine disorders, with the primary goal of improving patient outcomes and lives.

Diurnal’s product exclusivity is based around specific orphan drug designations, a patented portfolio spanning several product families and in-depth know-how of matching drug delivery solutions to clinical needs.

Market: AIM

Ticker: DNL


Lead analyst: Dr Martin Hall

Request a meeting

If you'd like to be introduced to the team at Diurnal Group Plc, get in touch.

Request a meeting